On July 2, 2025, Wondfo Biotech officially signed a strategic cooperation agreement on global localized production with Shanghai Kinbio Biotech Co., Ltd. (hereinafter referred to as "Kinbio").
 
The two companies will integrate their strengths in biotechnology, manufacturing, and intelligent production to provide international partners with one-stop solutions for the production and distribution of rapid diagnostic reagents.
 
This partnership represents a key step in Wondfo’s ongoing global strategy to enhance localized production capabilities, promote the coordinated development of regional healthcare systems, and jointly safeguard public health.
 

At the signing ceremony, Mr. Mark Xu, Vice President and Head of international Sales & Marketing Center of Wondfo, and Mr. Zhongren Zhou, Founder of Kinbio, signed the agreement on behalf of their respective companies.

Together, the two parties will accelerate the implementation of localized production projects, expand their footprint in developing countries, and help reduce reliance on imported diagnostic reagents.
 
Wondfo began its global journey as early as 2002. With a strong presence in over 150 countries and regions, Wondfo has built extensive access and distribution networks and established localized production bases in multiple countries to better serve global markets.
 
Kinbio offers distinct advantages in IVD production line automation from 2003. It’s a leading manufacturer of both equipment and components/material for rapid diagnostic product which includes reel to card production line, automated assembling and filling machine in Shanghai Pudong.    
 
Racing for Life, Wondfo and Kinbio will join forces to strengthen technological and supply chain collaboration—improving global health and advancing biotechnology to benefit society!